FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563704703> ?p ?o ?g. }

• W2563704703 abstract "Abstract Abstract 1553 Background and Aim The number and type of lymphocytes and monocytes/macrophages detectable in the peripheral blood and the lymph nodes of patients with Hodgkin and non-Hodgkin lymphomas has been recently extensively investigated and interesting results indicate they may possibly affect the pathogenesis and prognosis of these diseases. Recent results indicate that the lymphocyte/monocyte ratio (LMR), when assessed at diagnosis by a simple automatic blood count, may predict the clinical outcome of diffuse large B cell lymphoma patients (DLBCL) treated with the R-CHOP chemotherapy program (Li Z-M et al.: PLoS ONE 7(7):2012). The main objective of our study was to evaluate whether: a) the prognostic value of LMR could be confirmed either in patients treated with CHOP and Rituximab (R-CHOP) as well as in those treated with CHOP alone and b) the LMR could improve the prognostic profile as defined by the International Prognostic Index (IPI). Patients and Methods We retrospectively reviewed the clinical outcome of 973 DLBCL patients treated (549 with R-CHOP) and regularly followed at our institutions from 1984 to 2012. The median age of this patients cohort was 61 years (range, 18–86), the Male/Female ratio 55% and the median follow up 44 months (range, 2 – 330). According to the IPI score, 61% of patients were in the low (0–2) risk group, while 39% were in the intermediate or high-risk groups (3–5). A receiver operating characteristic (ROC) curve analysis was used to illustrate in our data set the best cut off values of peripheral blood lymphocyte absolute count (ALC), monocyte absolute count (AMC) or LMR. The relationship between IPI and the LMR was analyzed by the Fisher exact test. Univariate analysis to evaluate differences between variables was performed by the log rank. A multivariate analysis was performed by Cox proportional-hazards models. Results A preliminary ROC curve analysis performed on all patients (treated with or without rituximab) failed to identify any meaningful relationship between Overall Survival (OS) and the ALC, the AMC or the LMR. However, when the same analysis was restricted to patients treated with R-CHOP, we could confirm not only the positive correlation between ALC and AMC and OS, but most importantly that a LMR value >2.6 is the most sensitive (70%) and specific (53%) cut off to predict the OS. Within the R-CHOP treated cohort (N=549), we further investigated the relationships between LMR and the most relevant clinical features measured at diagnosis. Patients with a LMR ≤ 2.6 (52%) had a worst ECOG PS (p= 0.000), a higher LDH level (P= 0.000), a higher IPI (p= 0.000) and more frequently they were male (p= 0.02) and had an advanced Ann Arbor disease stage (p= 0.002). On the contrary, no statistical correlation was observed with age and the presence of extranodal sites. The proportion of patients achieving a complete response or a very good partial response was 95% in patients with a LMR >2.6 and 87% for those with a LMR ≤ 2.6 (p=0.018). More interestingly, among patients failing to achieve CR the proportion of those with a LMR ≤ 2.6 was 79% as compared to 21% among those with a LMR >2.6. The Event Free Survival of patients with a LMR >2.6 was significantly better when compared to those with a LMR ≤ 2.6 (71% vs. 59% at 5 years, p= 0.01) while no difference was observed for the Disease Free Survival. By univariate and multivariate analysis we could show that, similarly to a high IPI, a LMR ≤ 2.6 strongly predict a poor OS (p= 0.0000) (Figure 1). In addition, we could demonstrate a strong interaction between IPI and LMR since patients with a high IPI and LMR ≤ 2.6 are characterized by a very poor prognosis when compared to all the others (p= 0.000). Conclusions Our results confirm that a LMR ≤ 2.6 when assessed at diagnosis by a simple automatic blood count is not only a strong predictor of poor survival but it may help to better define a very poor prognostic subgroup in R-CHOP treated DLBCL. This novel prognostic marker is irrelevant when applied to patients receiving chemotherapy alone, giving further support to the notion that lymphocytes and/or monocytes play a crucial role on the therapeutic activity of Rituximab. Disclosures: Rambaldi: Hoffman-La Roche: Consultancy, Honoraria. Ladetto:Hoffman-La Roche: Consultancy, Honoraria. Gianni:Hoffman-La Roche: Consultancy, Honoraria. Tarella:Hoffman-La Roche: Consultancy, Honoraria." @default.
• W2563704703 created "2017-01-06" @default.
• W2563704703 creator A5005956018 @default.
• W2563704703 creator A5007938116 @default.
• W2563704703 creator A5010723896 @default.
• W2563704703 creator A5020522150 @default.
• W2563704703 creator A5030934542 @default.
• W2563704703 creator A5036758340 @default.
• W2563704703 creator A5038898384 @default.
• W2563704703 creator A5055401685 @default.
• W2563704703 creator A5058066073 @default.
• W2563704703 creator A5058765211 @default.
• W2563704703 creator A5064975574 @default.
• W2563704703 creator A5076353357 @default.
• W2563704703 creator A5087294312 @default.
• W2563704703 creator A5087360250 @default.
• W2563704703 creator A5087781254 @default.
• W2563704703 date "2012-11-16" @default.
• W2563704703 modified "2023-09-28" @default.
• W2563704703 title "The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab" @default.
• W2563704703 doi "https://doi.org/10.1182/blood.v120.21.1553.1553" @default.
• W2563704703 hasPublicationYear "2012" @default.
• W2563704703 type Work @default.
• W2563704703 sameAs 2563704703 @default.
• W2563704703 citedByCount "2" @default.
• W2563704703 countsByYear W25637047032013 @default.
• W2563704703 countsByYear W25637047032014 @default.
• W2563704703 crossrefType "journal-article" @default.
• W2563704703 hasAuthorship W2563704703A5005956018 @default.
• W2563704703 hasAuthorship W2563704703A5007938116 @default.
• W2563704703 hasAuthorship W2563704703A5010723896 @default.
• W2563704703 hasAuthorship W2563704703A5020522150 @default.
• W2563704703 hasAuthorship W2563704703A5030934542 @default.
• W2563704703 hasAuthorship W2563704703A5036758340 @default.
• W2563704703 hasAuthorship W2563704703A5038898384 @default.
• W2563704703 hasAuthorship W2563704703A5055401685 @default.
• W2563704703 hasAuthorship W2563704703A5058066073 @default.
• W2563704703 hasAuthorship W2563704703A5058765211 @default.
• W2563704703 hasAuthorship W2563704703A5064975574 @default.
• W2563704703 hasAuthorship W2563704703A5076353357 @default.
• W2563704703 hasAuthorship W2563704703A5087294312 @default.
• W2563704703 hasAuthorship W2563704703A5087360250 @default.
• W2563704703 hasAuthorship W2563704703A5087781254 @default.
• W2563704703 hasConcept C126322002 @default.
• W2563704703 hasConcept C143998085 @default.
• W2563704703 hasConcept C203014093 @default.
• W2563704703 hasConcept C2777761686 @default.
• W2563704703 hasConcept C2778476033 @default.
• W2563704703 hasConcept C2778559949 @default.
• W2563704703 hasConcept C2779338263 @default.
• W2563704703 hasConcept C2779725641 @default.
• W2563704703 hasConcept C2780653079 @default.
• W2563704703 hasConcept C58471807 @default.
• W2563704703 hasConcept C71924100 @default.
• W2563704703 hasConcept C90924648 @default.
• W2563704703 hasConceptScore W2563704703C126322002 @default.
• W2563704703 hasConceptScore W2563704703C143998085 @default.
• W2563704703 hasConceptScore W2563704703C203014093 @default.
• W2563704703 hasConceptScore W2563704703C2777761686 @default.
• W2563704703 hasConceptScore W2563704703C2778476033 @default.
• W2563704703 hasConceptScore W2563704703C2778559949 @default.
• W2563704703 hasConceptScore W2563704703C2779338263 @default.
• W2563704703 hasConceptScore W2563704703C2779725641 @default.
• W2563704703 hasConceptScore W2563704703C2780653079 @default.
• W2563704703 hasConceptScore W2563704703C58471807 @default.
• W2563704703 hasConceptScore W2563704703C71924100 @default.
• W2563704703 hasConceptScore W2563704703C90924648 @default.
• W2563704703 hasLocation W25637047031 @default.
• W2563704703 hasOpenAccess W2563704703 @default.
• W2563704703 hasPrimaryLocation W25637047031 @default.
• W2563704703 hasRelatedWork W2080576951 @default.
• W2563704703 hasRelatedWork W2179492509 @default.
• W2563704703 hasRelatedWork W2338351021 @default.
• W2563704703 hasRelatedWork W2366413926 @default.
• W2563704703 hasRelatedWork W2492791618 @default.
• W2563704703 hasRelatedWork W2512811470 @default.
• W2563704703 hasRelatedWork W2515385750 @default.
• W2563704703 hasRelatedWork W2522667622 @default.
• W2563704703 hasRelatedWork W2548493054 @default.
• W2563704703 hasRelatedWork W2554558313 @default.
• W2563704703 hasRelatedWork W2556535133 @default.
• W2563704703 hasRelatedWork W2565527293 @default.
• W2563704703 hasRelatedWork W2587826297 @default.
• W2563704703 hasRelatedWork W2588345046 @default.
• W2563704703 hasRelatedWork W2590218516 @default.
• W2563704703 hasRelatedWork W2592698878 @default.
• W2563704703 hasRelatedWork W2928453788 @default.
• W2563704703 hasRelatedWork W2995560577 @default.
• W2563704703 hasRelatedWork W3096138557 @default.
• W2563704703 hasRelatedWork W2610784030 @default.
• W2563704703 isParatext "false" @default.
• W2563704703 isRetracted "false" @default.
• W2563704703 magId "2563704703" @default.
• W2563704703 workType "article" @default.